X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
TEVA PHARMA
Dec-13
AJANTA PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7202,683-   
Low Rs1,1032,330-   
Sales per share (Unadj.) Rs194.61,539.6-  
Earnings per share (Unadj.) Rs45.296.2-  
Cash flow per share (Unadj.) Rs50.3220.6-  
Dividends per share (Unadj.) Rs8.0084.19-  
Dividend yield (eoy) %0.63.4 16.9%  
Book value per share (Unadj.) Rs132.01,710.2-  
Shares outstanding (eoy) m88.77848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.6 445.5%   
Avg P/E ratio x31.226.1 119.8%  
P/CF ratio (eoy) x28.111.4 247.0%  
Price / Book Value ratio x10.71.5 729.4%  
Dividend payout %17.787.5 20.2%   
Avg Mkt Cap Rs m125,2992,125,537 5.9%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m2,5700-   
Avg. sales/employee Rs ThNM29,048.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM1,814.6-  
INCOME DATA
Net Sales Rs m17,2751,305,581 1.3%  
Other income Rs m1660-   
Total revenues Rs m17,4421,305,581 1.3%   
Gross profit Rs m5,807357,534 1.6%  
Depreciation Rs m451105,531 0.4%   
Interest Rs m4925,644 0.2%   
Profit before tax Rs m5,474226,359 2.4%   
Minority Interest Rs m01,028 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-148,592 0.0%   
Tax Rs m1,460-2,764 -52.8%   
Profit after tax Rs m4,01481,559 4.9%  
Gross profit margin %33.627.4 122.8%  
Effective tax rate %26.7-1.2 -2,184.4%   
Net profit margin %23.26.2 372.0%  
BALANCE SHEET DATA
Current assets Rs m7,639881,784 0.9%   
Current liabilities Rs m2,715768,991 0.4%   
Net working cap to sales %28.58.6 329.9%  
Current ratio x2.81.1 245.4%  
Inventory Days Days4391 47.6%  
Debtors Days Days7996 82.0%  
Net fixed assets Rs m6,914426,431 1.6%   
Share capital Rs m1773,214 5.5%   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,7211,450,253 0.8%   
Long term debt Rs m149667,572 0.0%   
Total assets Rs m14,8142,983,670 0.5%  
Interest coverage x112.99.8 1,149.3%   
Debt to equity ratio x00.5 2.8%  
Sales to assets ratio x1.20.4 266.5%   
Return on assets %27.43.6 763.3%  
Return on equity %34.25.6 609.0%  
Return on capital %46.54.9 943.6%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,264208,042 1.6%  
From Investments Rs m-2,093-73,718 2.8%  
From Financial Activity Rs m-1,186-249,560 0.5%  
Net Cashflow Rs m-15-115,236 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare AJANTA PHARMA With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC PHARMA  GSK PHARMA  NOVARTIS  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS